TY  - JOUR
AU  - Wen, Yujie
AU  - Chhabra, Anita Y.
AU  - Ildstad, Suzanne T.
AU  - Leventhal, Joseph R.
PY  - 2018
DA  - 2018/11/20
TI  - Allogeneic Hematopoietic Cell Therapies to Induce Tolerance in Kidney Transplantation
JO  - OBM Transplantation
SP  - 027
VL  - 02
IS  - 04
AB  - This review summarizes the latest results from the interventional clinical trials for inducing clinical tolerance in the recipients of human leukocyte antigen (HLA)-matched or mismatched living donor kidney transplants via allogeneic hematopoietic stem cell (HSC)-based therapies. The protocols utilized by the three medical centers in the United States differ in degree of HLA-matching, relatedness or unrelatedness, donor cell composition of the hematopoietic stem cells transplant (HSCT), timing for infusion and conditioning regimens. Tolerant recipients from the clinical trials benefited from better long-term outcome, improved quality of life and reduction in lifetime healthcare expenses compared with standard-of-care recipients on conventional immunosuppression. Durable chimerism induced by concomitant HSCT is indispensable to achieve immunologic tolerance to kidney transplantation and to protect against recurrence of the original renal disease in HLA-mismatched related and unrelated kidney transplant recipients.
SN  - 2577-5820
UR  - https://doi.org/10.21926/obm.transplant.1804027
DO  - 10.21926/obm.transplant.1804027
ID  - Wen2018
ER  -